Expression and role of 17BETA-hydroxysteroid dehydrogenase type 1, 5 and 7 in epithelial ovarian cancer

Authors: Wang, Ruixuan
Advisor: Lin, Sheng-Xiang
Abstract: Ovarian cancer is one of the top five commonest causes of female cancer death in the developed world. About 90% of ovarian cancer have epithelial origins. Epithelial ovarian cancer (EOC) is a hormone-dependent cancer, in which the sex steroids play a crucial role in maintaining the cell proliferation and survival. The 17β-hydroxysteroid dehydrogenases (17β-HSDs) are important in the control of intracellular concentration of all active sex steroids. The function and expression of 17β-HSDs in EOC is not fully understood. Whether or not 17β-HSDs could be a therapeutic approach for the EOC treatment needs to be studied. Our results showed that 17β-HSD types 1, 5 and 7 are all expressed in EOC cells OVCAR-3 and type 1 is the highest one. The expression of 17β-HSD types 1 and 7 is higher in epithelial ovarian tumor tissues than in normal ovaries (type1, 2.2-fold; type7, 1.9-fold), but the expression of 17β-HSD type 5 is significantly lower in the tumor, following the EOC development (-5.2-fold). We found that cell proliferation was decreased after 17β-HSD type 1 or 7 knockdown by specific siRNAs in OVCAR-3 cells. While knocking down type 5 has the opposite effect. We suggest that 17β- HSD type 5 may be involved in steroid hormone signaling in EOC development. Moreover, 17β-HSD types 1 and 7 could be important biomarkers for early diagnosed EOC and novel targets for EOC treatment.
Document Type: Mémoire de maîtrise
Issue Date: 2018
Open Access Date: 7 May 2018
Permalink: http://hdl.handle.net/20.500.11794/29632
Grantor: Université Laval
Collection:Thèses et mémoires

Files in this item:
SizeFormat 
33859.pdf3.43 MBAdobe PDFView/Open
All documents in CorpusUL are protected by Copyright Act of Canada.